Sirt1/2-IN-3_product_DataBase

Bioactivity	Sirt1/2-IN-3 (compound PS9) is a dual inhibitor of SIRT1/2 with IC50s of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respsectivley. Sirt1/2-IN-3 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-3 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines[1].
Target	IC50: 1.4 μM (SIRT1), 2.0 μM (SIRT2), 72.3 μM (SIRT3)
Invitro	Sirt1/2-IN-3 (compound hsa55) (5 μM; 48 h) 诱导不同肿瘤细胞凋亡，IC50 分别为 6.5 μM (MV4-11)、9.2μM (MOLM-13)、27.2 μM (THP1)、17.4 μM (Jurkat)[1]。Sirt1/2-IN-3 (100 μM; 30 min) 会降低 SIRT1 和 SIRT2 蛋白在不同温度下的热稳定性，并且 (25 μM、30 μM; 24 h) 会增加 MOLM-13 细胞中 p53 和 α 微管蛋白乙酰化形式的水平[1]。 0 --> Sirt1/2-IN-3 相关抗体:
Name	Sirt1/2-IN-3
CAS	301313-42-8
Formula	C17H14ClNO4S
Molar Mass	363.82
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Cai H, et al. Discovery of Novel SIRT1/2 Inhibitors with Effective Cytotoxicity against Human Leukemia Cells. J Chem Inf Model. 2023 Aug 14;63(15):4780-4790.

PeptideDB